Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield agitation inventory

被引:0
|
作者
Koss, E
Weiner, M
Ernesto, C
CohenMansfield, J
Ferris, SH
Grundman, M
Schafer, K
Sano, M
Thal, LJ
Thomas, R
Whitehouse, PJ
机构
[1] CASE WESTERN RESERVE UNIV, DEPT NEUROL, CLEVELAND, OH 44106 USA
[2] UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, HOUSTON, TX USA
[3] HEBREW HOME GREATER WASHINGTON, WASHINGTON, DC USA
[4] GEORGETOWN UNIV, WASHINGTON, DC USA
[5] NYU, MED CTR, DEPT PSYCHIAT, AGING & DEMENTIA RES CTR, NEW YORK, NY 10016 USA
[6] COLUMBIA UNIV, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY USA
[7] UNIV CALIF SAN DIEGO, DEPT NEUROSCI, SAN DIEGO, CA 92103 USA
[8] UNIV CALIF SAN DIEGO, ALZHEIMERS DIS COOPERAT STUDY, SAN DIEGO, CA 92103 USA
关键词
Alzheimer's Disease Cooperative Study; agitation; Alzheimer's disease; Cohen-Mansfield Agitation Inventory; longitudinal changes; reliability; temporal patterns;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As part of the effort of the NIA Alzheimer's disease cooperative study to develop improved instruments for quantifying effects in Alzheimer's disease (AD) clinical trials, patterns of agitated behaviors were evaluated with the Cohen-Mansfield Agitation Inventory (CMAI) in 241 AD patients and 64 healthy elderly controls with valid baseline assessment on the CMAI, The test-retest reliability of the CMAI over 1 month was good (r = 0.74 to 0.92). Physically and verbally nonaggressive behaviors were most often reported, whereas physically aggressive behaviors were rare. Frequency of agitated behaviors increased with dementia severity, especially for patients with a Mini-Mental Status Exam score of 0-4. Agitation tended to increase in the evening with dementia severity for the more impaired patients. Amount of agitation did increase after 12 months in all but controls and mildly demented patients, The CMAI shows promise for evaluating a unique aspect of behavior and may be useful in assessing the effects of cognitive enhancers and other types of psychotropic drugs on behavior in dementia patients.
引用
收藏
页码:S45 / S50
页数:6
相关论文
共 50 条
  • [21] Cannabinoids for Agitation in Alzheimer's Disease
    Outen, John D.
    Burhanullah, M. Haroon
    Vandrey, Ryan
    Amjad, Halima
    Harper, David G.
    Patrick, Regan E.
    May, Rose L.
    Agronin, Marc E.
    Forester, Brent P.
    Rosenberg, Paul B.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 29 (12) : 1253 - 1263
  • [22] Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease
    Martin, J
    Marler, M
    Shochat, T
    Ancoli-Israel, S
    CHRONOBIOLOGY INTERNATIONAL, 2000, 17 (03) : 405 - 418
  • [23] Pharmacologic management of agitation in Alzheimer's disease
    Profenno, LA
    Tariot, PN
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 17 (1-2) : 65 - 77
  • [24] Advancements in the treatment of agitation in Alzheimer's disease
    Antonsdottir, Inga M.
    Smith, Jessica
    Keltz, Melanie
    Porsteinsson, Anton P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (11) : 1649 - 1656
  • [25] Agitation and aggression in people with Alzheimer's disease
    Ballard, Clive
    Corbett, Anne
    CURRENT OPINION IN PSYCHIATRY, 2013, 26 (03) : 252 - 259
  • [26] Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria
    De Mauleon, Adelaide
    Ismail, Zahinoor
    Rosenberg, Paul
    Miller, David
    Cantet, Christelle
    O'Gorman, Cedric
    Vellas, Bruno
    Lyketsos, Constantine
    Soto, Maria
    ALZHEIMERS & DEMENTIA, 2021, 17 (10) : 1687 - 1697
  • [27] The neurochemistry of agitation in Alzheimer's disease: a systematic review
    Liu, Kathy Y.
    Stringer, Aisling E.
    Reeves, Suzanne J.
    Howard, Robert J.
    AGEING RESEARCH REVIEWS, 2018, 43 : 99 - 107
  • [28] Role of citalopram in the treatment of agitation in Alzheimer's disease
    Porsteinsson, Anton P.
    Keltz, Melanie A.
    Smith, Jessica S.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2014, 4 (05) : 345 - 349
  • [29] An update on the advancements in the treatment of agitation in Alzheimer's disease
    Porsteinsson, Anton P.
    Antonsdottir, Inga M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (06) : 611 - 620
  • [30] Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation
    Oguma, Takuya
    Jino, Kohei
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2024, 72 (07) : 610 - 617